Roche Holding AG Stock Deutsche Boerse AG

Equities

RHO5

CH0012032048

Pharmaceuticals

Delayed Deutsche Boerse AG 11:41:42 2019-06-28 am EDT 5-day change 1st Jan Change
245.6 EUR -0.14% Intraday chart for Roche Holding AG -.--% -.--%

Financials

Sales 2024 * 59.97B 65.65B 61.23B Sales 2025 * 63.83B 69.88B 65.17B Capitalization 179B 196B 183B
Net income 2024 * 13.32B 14.58B 13.6B Net income 2025 * 14.75B 16.15B 15.06B EV / Sales 2024 * 3.22 x
Net Debt 2024 * 13.91B 15.23B 14.2B Net Debt 2025 * 7.76B 8.5B 7.93B EV / Sales 2025 * 2.93 x
P/E ratio 2024 *
13.1 x
P/E ratio 2025 *
11.9 x
Employees 103,605
Yield 2024 *
4.38%
Yield 2025 *
4.53%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart
5 years
226.40
Extreme 226.4
253.80
10 years
178.38
Extreme 178.38
274.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 65 95-12-31
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
222.2 CHF
Average target price
281.1 CHF
Spread / Average Target
+26.49%
Consensus